Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, placebo-controlled study to investigate safety, tolerability, immunogenicity and clinical efficacy of a specific immunotherapy combining allergen with CYT003-QbG10 (CYT005-AllQbG10) in adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy

Next Previous
X
Search
Trial Profile

Double-blind, placebo-controlled study to investigate safety, tolerability, immunogenicity and clinical efficacy of a specific immunotherapy combining allergen with CYT003-QbG10 (CYT005-AllQbG10) in adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYT 005 AllQbG10 (Primary) ; House dust mite allergy immunotherapy; Vaccines
  • Indications Hypersensitivity; Perennial allergic rhinitis; Rhinoconjunctivitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 May 2009 Additional lead investigator (Mueller P) identified as reported by ClinicalTrials.gov
    • 10 Jul 2008 Status changed from in progress to completed, based on results data reported in Cytos media release.
    • 21 Jun 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top